Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -77.91M | -81.75M | -85.96M | -83.75M | -80.56M |
| Total Depreciation and Amortization | 1.36M | 1.30M | 1.20M | 1.09M | 1.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.31M | 14.88M | 13.44M | 12.13M | 11.44M |
| Change in Net Operating Assets | -2.43M | -212.00K | 486.00K | 2.41M | 2.44M |
| Cash from Operations | -63.67M | -65.79M | -70.83M | -68.12M | -65.67M |
| Capital Expenditure | -1.67M | -2.28M | -2.37M | -2.01M | -2.77M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.77M | 61.27M | 71.46M | -36.40M | -49.00M |
| Cash from Investing | 66.10M | 58.99M | 69.09M | -38.41M | -51.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.00K | 1.00K | 1.00K | 70.01M | 70.09M |
| Repurchase of Common Stock | -750.00K | -1.21M | -2.29M | -2.70M | -2.52M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -307.00K | 53.55M | 53.46M |
| Cash from Financing | -749.00K | -1.20M | -2.59M | 120.86M | 121.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.69M | -8.00M | -4.33M | 14.33M | 3.59M |